Eric Yuen, M.D., is a clinical development physician with over 30 years of experience in academia (7 years) and industry (>20 years). He has developed biologics and small molecules for a variety of diseases, including rare genetic, neurology, psychiatry, pain, and oncology disorders. Eric has held several senior positions at Merck (2000-2004), Johnson & Johnson (2004-2013), Ultragenyx (2013), BioClin (2014), RiboNova (2015-2019), and Inozyme (2017-2019) which included Vice President CNS Therapeutic Area Head at Johnson & Johnson, Vice President Head of Clinical Development at Janssen Alzheimer Immunotherapy, and Chief Medical Officer at Ultragenyx, RiboNova and Inozyme. He is a co-founder and Chief Medical Officer at Talee Bio, which was acquired by Roivant then Sumitomo Dainippon and renamed Spirovant Sciences (2016-2023), then spun out from Sumitomo in 2024. Eric also serves on the Scientific Advisory Boards at Asceneuron, Nitrase Therapeutics and RiboNova, and as a consulting Chief Medical Officer at Abyssinia Biologics and Nitrase Therapeutics. Eric has led departments responsible for Phase I-III and preclinical development and submissions of numerous INDs, CTAs, NDAs and MAAs. From 1996-2000, Eric was a faculty member at the University of Washington, serving as an assistant professor and clinical researcher, studying treatments for ALS, neuropathy and multiple sclerosis. Eric received his undergraduate education at Stanford University and his M.D. from the University of Chicago, Pritzker School of Medicine. He completed his residency in neurology and post-doctoral fellowships at the University of California, San Francisco.